Form 8-K - Current report:
SEC Accession No. 0001213900-25-120676
Filing Date
2025-12-11
Accepted
2025-12-11 16:10:55
Documents
14
Period of Report
2025-12-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0268925-8k_oruka.htm   iXBRL 8-K 46590
2 OFFER LETTER, DATED DECEMBER 1, 2025, BETWEEN ORUKA THERAPEUTICS, INC. AND CHRIS ea026892501ex10-1_oruka.htm EX-10.1 13431
3 GRAPHIC ex10-1_001.jpg GRAPHIC 6156
  Complete submission text file 0001213900-25-120676.txt   240134

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE orka-20251211.xsd EX-101.SCH 3011
5 XBRL LABEL FILE orka-20251211_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE orka-20251211_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0268925-8k_oruka_htm.xml XML 3694
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 251565098
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)